Erasca announces pricing of upsized public offering of common stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, has announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, generating expected gross proceeds of $225.0 million before underwriting discounts and expenses. The offering includes an option for underwriters to purchase up to an additional 3,375,000 shares within 30 days. The transaction is expected to close on January 23, 2026, subject to customary conditions.

The company plans to use the net proceeds, along with existing cash and marketable securities, to advance research and development of its product candidates and for general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers for the offering.

The offering is conducted under a shelf registration statement on Form S-3 filed with the SEC. Investors may obtain copies of the prospectus supplement and accompanying prospectus from the underwriters or via the SEC’s website.